Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the primary endpoint of complete renal response (CRR) compared with standard therapy alone in achieving the primary endpoint of complete renal response, compared to standard therapy alone.
Of those treated with Gazyva plus standard therapy (mycophenolate mofetil and glucocorticoids), 46.4% achieved complete renal response at 76 weeks compared with 33.1% of people treated with standard therapy alone. Lupus nephritis is a severe kidney disease caused by systemic lupus erythematosus.
